🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Heidelberg
Clinical trial register · Germany

Clinical Trials in Heidelberg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital Heidelberg50 AstraZeneca33 Janssen Research & Development, LLC27 Merck Sharp & Dohme LLC18 Hoffmann-La Roche17
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Heidelberg

627 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
DrugsSurovatamig·R-Chop
AstraZeneca
Phase 3
1,018
Berlin, Deggendorf, Düsseldorf, Göttingen, Hamburg, Heidelberg, Jena, Karlsruhe
2024-08-07
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Heidelberg, Erdgeschoss, Düsseldorf
2024-08-07
Recruiting
Targeted Pediatric High-Grade Glioma Therapy
NCT05839379High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma
Nationwide Children's Hospital
Observational
350
Heidelberg
2024-08-02
Recruiting
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NCT06216301Metastatic Non-small Cell Lung Cancer
DrugPembrolizumab
NovoCure GmbH
Phase 3
734
Berlin, Giessen, Halle, Heidelberg, Löwenstein, Oldenburg
2024-07-31
Active, closed
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816Geographic Atrophy
DrugVonaprument
Annexon, Inc.
Phase 3
659
Neubrandenburg, Münster, Bonn, Heidelberg, Tübingen
2024-07-30
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180Cervical Cancer
DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
686
Heidelberg, Heilbronn, Schwäbisch Hall, Munich, Marburg, Düsseldorf, Essen, Worms
2024-07-24
Recruiting
PulseSelect™ PFA Global Registry
NCT06393920Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
1,950
Frankfurt, Heidelberg, Ludwigshafen am Rhein, Paderborn
2024-07-23
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin
Jazz Pharmaceuticals
Phase 3
286
Freiburg im Breisgau, Heidelberg, Tübingen, München, Frankfurt am Main, Hanover, Dresden, Lübeck
2024-07-19
Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883Inflammatory Bowel Diseases, Crohn's Disease
DrugZotemtegrast
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
Berlin, Dachau, Duisburg, Frankfurt am Main, Halle, Heidelberg, Kiel, Leipzig
2024-07-18
Recruiting
TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic Ataxias
NCT07798674Hereditary Spastic Paraplegia, Spastic Ataxia
Heidelberg University
Observational
4,000
Bochum, Bonn, Dresden, Erlangen, Essen, Göttingen, Heidelberg, Kiel
2024-07-16
Recruiting
Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.
NCT06784778Melanoma Metastatic, Melanoma, Skin, Melanoma Stage III or IV, Melanoma Advanced
Pamgene International B.V.
Observational
196
Tübingen, Heidelberg, München
2024-07-12
Recruiting
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180Advanced Melanoma
DrugsVusolimogene Oderparepvec·Relatlimab·Opdivo·Keytruda
Replimune, Inc.
Phase 3
400
Berlin, Dresden, Erfurt, Essen, Hamburg, Heidelberg, Kiel, Mainz
2024-07-11
Recruiting
An International, Multicenter, Prospective Registry on Post-traumatic Long Bones Defects
NCT04112992Limb Fracture, Bone Loss
AO Innovation Translation Center
Observational
600
Frankfurt, Giessen, Heidelberg, Münster, Wildeshausen
2024-07-03
Recruiting
Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy
NCT06369142Coronary Artery Disease
Deutsches Herzzentrum Muenchen
Not applicable
666
Heidelberg, Mannheim, Singen, Ulm, Augsburg, Dachau, Erding, Ingolstadt
2024-07-01
Not yet open
Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging
NCT03865277Head and Neck Squamous Cell Carcinoma
Technische Universität Dresden
Phase 2
276
Freiburg im Breisgau, Heidelberg, Mannheim, Würzburg, Dresden, Leipzig, Berlin, München
2024-07-01
Active, closed
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NCT06388733Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
DrugsTemodar·Niraparib·Temozolomide
Ivy Brain Tumor Center
Phase 3
450
Heidelberg, Mannheim, Tübingen, Regensburg, Bonn, Chemnitz, Leipzig, Berlin
2024-06-19
Active, closed
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991Multiple Myeloma
DrugTeclistamab
Janssen Research & Development, LLC
Phase 1
108
Chemnitz, Hamburg, Heidelberg, Würzburg
2024-06-07
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
Cologne, Dresden, Essen, Gauting, Großhansdorf, Heidelberg, Münster, Würzburg
2024-06-05
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
DrugsNavtemadlin·Jakavi·Ruxolitinib
Kartos Therapeutics, Inc.
Phase 3
600
Düsseldorf, Freiburg im Breisgau, Halle, Hamburg, Hanover, Heidelberg, Jena, Kiel
2024-06-03
Active, closed
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
DrugsAnvumetostat·Modified FOLFIRINOX·Cetuximab·Nab-paclitaxel
Amgen
Phase 1
120
Essen, Heidelberg, Würzburg
2024-05-29
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
DrugsTucatinib·Disitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Berlin, Essen, Heidelberg
2024-05-20
Recruiting
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386Prostatic Neoplasms, Castration-Resistant
DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Olaparib
Merck Sharp & Dohme LLC
Phase 1/2
220
Heidelberg, Tübingen, Munich, Berlin, Hamburg
2024-05-20
Active, closed
The OPBC-07/microNAC Study
NCT06529302Breast Cancer
University Hospital, Basel, Switzerland
Observational
2,000
Augsburg, Düsseldorf, Essen, Heidelberg, Lübeck
2024-05-15
Recruiting
Corheart 6 LVAS Study
NCT05876000Refractory Heart Failure
Shenzhen Core Medical Technology CO.,LTD.
Not applicable
53
Bad Oeynhausen, Berlin, Bremen, Hamburg, Heidelberg, Leipzig, Würzburg
2024-05-14
Active, closed
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311Gastroesophageal Cancer
DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
450
Heidelberg, Göttingen, Dresden, Kiel, Berlin, Hamburg
2024-05-03
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
NCT05976685Ischemic Stroke, Atrial Fibrillation
DrugDOAC
Insel Gruppe AG, University Hospital Bern
Not applicable
482
Lübeck, Berlin, Bonn, Göttingen, Hamburg, Heidelberg, Leipzig, Mannheim
2024-05-01
Active, closed
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
470
Freiburg im Breisgau, Heidelberg, Tübingen, Augsburg, München, Blankenfelde-Mahlow, Darmstadt, Frankfurt am Main
2024-04-29
Active, closed
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008Perennial Allergic Rhinitis (PAR)
DrugLebrikizumab
Eli Lilly and Company
Phase 3
450
Berlin, Dresden, Frankfurt am Main, Heidelberg, Marburg, Weisbaden
2024-04-26
Recruiting
BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation
NCT05717192Emphysema or Chronic Obstructive Pulmonary Disease
IHF GmbH - Institut für Herzinfarktforschung
Not applicable
224
Berlin, Bonn, Essen, Halle, Heidelberg, Hemer, Immenhausen, Langen
2024-04-24
Recruiting
Sacituzumab Govitecan in Metastatic Colorectal Cancer
NCT06243393Metastatic Colorectal Cancer
DrugSacituzumab Govitecan
University Hospital Heidelberg
Phase 2/3
80
Heidelberg
2024-04-19
Active, closed
A Study of Barzolvolimab in Patients With Prurigo Nodularis
NCT06366750Prurigo Nodularis
DrugBarzolvolimab
Celldex Therapeutics
Phase 2
140
Augsburg, Bad Bentheim, Berlin, Bochum, Erlangen, Frankfurt, Heidelberg, Münster
2024-04-12
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064Recurrent or Metastatic Solid Tumors
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
680
Heidelberg, Heilbronn, Münster, Mainz, Dresden, Leipzig, Berlin
2024-04-10
Recruiting
Cohort Study on Plant-based Diets (COPLANT Study)
NCT06323538Dietary Exposure, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Bone Loss
German Federal Institute for Risk Assessment
Observational
6,000
Karlsruhe, Jena, Berlin, Bonn, Giessen, Heidelberg, Regensburg
2024-04-09
Active, closed
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06245408Sjögren's Syndrome (SS)
DrugDazodalibep
Amgen
Phase 3
434
Heidelberg, Bad Doberan, Greifswald Hansestadt, Chemnitz, Hamburg
2024-04-08
Recruiting
Prospective, Non-Randomised Clinical Trial to Investigate the BeGraft Aortic Stent Graft System and the BeGraft Peripheral Stent Graft System Treating Aortic-iliac Occlusive Disease
NCT05805111Aorto-iliac Occlusive Disease
Marc Bosiers, MD
Observational
109
Berlin, Frankfurt, Göttingen, Heidelberg, Lünen, Münster, Regensburg, Stuttgart
2024-04-05
Recruiting
Success Rates of Video- vs. Direct Laryngoscopy for Endotracheal Intubation in Anesthesiology Residents: A Randomized Controlled Trial" (The JuniorDoc-VL-Trial)
NCT06360328Intubation Complication, Intubation
University Hospital Heidelberg
Not applicable
30
Heidelberg
2024-04-01
Active, closed
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950Ulcerative Colitis
DrugZasocitinib
Takeda
Phase 2
213
Frankfurt am Main, Hamburg, Heidelberg, Kiel, Ludwigshafen, Tübingen, Ulm
2024-03-29
Recruiting
Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients
NCT05944016Chronic Kidney Failure in Children and Young Adults
DrugDapagliflozin
University Hospital Goettingen
Phase 3
102
Heidelberg, München, Hamburg, Frankfurt am Main, Göttingen, Cologne, Münster, Leipzig
2024-03-25
Recruiting
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
NCT05904119First Progression of Glioblastoma
DrugLomustine
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
411
Bochum, Cologne, Erlangen, Essen, Heidelberg, Leipzig, Munich, Regensburg
2024-03-15
Active, closed
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer
DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib
AstraZeneca
Phase 3
594
Berlin, Frankfurt, Göttingen, Hamburg, Heidelberg, Heilbronn, Leipzig, Marburg
2024-03-04
Recruiting
Predicting Esophageal Cancer Borders Using PET-Imaging
NCT06408116Esophagus Cancer, Stage I, Esophagus Cancer, Stage II
University Hospital Heidelberg
Phase 2
30
Heidelberg
2024-03-01
Recruiting
Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer
NCT06834152Localized Prostate Carcinoma, Prostate Cancer (Adenocarcinoma), Prostate Hyperplasia, Lower Urinary Track Symptoms
University of Zurich
Observational
75
Heidelberg, Munich
2024-03-01
Recruiting
Mentalization-based Treatment Versus Bona-fide Treatment for Patients With Borderline Personality Disorder in Germany
NCT06018272Borderline Personality Disorder
Heidelberg University
Not applicable
304
Berlin, Düsseldorf, Heidelberg, Jena, Ulm
2024-02-28
Recruiting
Exploring the Effects of Exercise on Memory and Cognition in Parkinson´s Disease
NCT06580977Parkinson Disease
Heidelberg University
Not applicable
60
Heidelberg
2024-02-27
Recruiting
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
NCT06035120Emphysema, Pulmonary, Emphysema or COPD
Pulmonx Corporation
Not applicable
200
Essen, Halle, Hamburg, Heidelberg, Hemer
2024-02-22
Active, closed
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435Carcinoma, Non-Small-Cell Lung
DrugsSigvotatug vedotin·Docetaxel
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Halle, Bonn, Esslingen am Neckar, Frankfurt a.M., Gauting, Großhansdorf, Heidelberg
2024-02-21
Recruiting
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
NCT06134492Pneumonia, Viral, Ventilator Associated Pneumonia, Community-acquired Pneumonia, Herpes Simplex
DrugAcyclovir
Jena University Hospital
Phase 3
616
Freiburg im Breisgau, Heidelberg, Tübingen, Augsburg, München, Nuremberg, Regensburg, Rosenheim
2024-02-20
Active, closed
A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis
NCT06260709Transthyretin Amyloid Cardiomyopathy (ATTR CM)
DrugNNC6019-0001
Novo Nordisk A/S
Phase 2
80
Heidelberg, München, Münster, Würzburg
2024-02-20
Active, closed
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140Carcinoma, Non-Small-Cell Lung
DrugsClobetasol·Minocycline·Chlorhexidine·Clindamycin
Janssen Research & Development, LLC
Phase 2
305
Aachen, Essen, Giessen, Heidelberg, Kassel, Kiel
2024-02-16
Active, closed
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
NCT05990738Small Cell Lung Carcinoma (SCLC)
DrugsObrixtamig·Topotecan
Boehringer Ingelheim
Phase 1
69
Dresden, Erlangen, Heidelberg, Mainz, Würzburg
2024-02-14
Recruiting
Removable Partial Dentures Made of PEEK
NCT06191107Tooth Loss
University Hospital Heidelberg
Not applicable
50
Heidelberg
2024-02-12
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin
Boehringer Ingelheim
Phase 3
428
Augsburg, Berlin, Cologne, Dresden, Giessen, Heidelberg, Oldenburg, Tübingen
2024-02-09
Recruiting
Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Patients
NCT07044427Multiple Myeloma, Fall Risk Factors, Strength Training Effects, Balance Training Effects
University Hospital Heidelberg
Not applicable
60
Heidelberg
2024-02-02
Active, closed
Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases
NCT05871307Brain Metastases, Radiotherapy
University Hospital Heidelberg
Not applicable
90
Heidelberg
2024-02-01
Recruiting
PROCARE - PROstate Cancer Real World Evidence Registry
NCT06835218Prostate Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate, Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
UroTrials Company (GmbH)
Observational
5,000
Freiburg im Breisgau, Heidelberg, Mannheim, Nürtingen, Tübingen, Ulm, Augsburg, Bayreuth
2024-01-29
Recruiting
The Pancreatic Enzymes After Gastrectomy Trial
NCT06058442Gastrectomy
University of Leipzig
Phase 3
188
Borna, Cottbus, Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Jena, Leipzig
2024-01-24
Recruiting
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06153251Relapsed and/or Refractory Multiple Myeloma
DrugsFludara·Cytoxan·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Cologne, Heidelberg, Würzburg
2024-01-23
Active, closed
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150Multiple Myeloma
DrugsElotuzumab·Velcade·Talquetamab·Teclistamab
Janssen Research & Development, LLC
Phase 3
838
Augsburg, Halle, Heidelberg, Magdeburg, München, Tübingen, Würzburg
2024-01-22
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Berlin, Cologne, Dresden, Frankfurt am Main, Heidelberg, Immenhausen, Moers
2024-01-18
Recruiting
Effectiveness of an Ecological Momentary Emotion Regulation Intervention
NCT06311136Depressive Disorder, Major, Persistent Depressive Disorder, Healthy
Heidelberg University
Not applicable
200
Heidelberg
2024-01-12
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugALXN2220
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Berlin, Cologne, Essen, Giessen, Hamburg, Hanover, Heidelberg, Homburg
2024-01-11
Recruiting
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
NCT06840119Cancer, HLA-A*02:01-positive
Immunocore Ltd
Phase 1/2
600
Heidelberg
2024-01-10
Recruiting
A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
NCT06205953AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
Observational
400
Heidelberg
2024-01-01
Recruiting
Register for Longitudinal Recording of Brain Function
NCT06401057Patients With Brain Masses/Lesions
University Hospital Heidelberg
Observational
1,000
Heidelberg
2024-01-01
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
DrugFrexalimab
Sanofi
Phase 3
943
Bielefeld, Bochum, Dresden, Düsseldorf, Erbach im Odenwald, Essen, Heidelberg, Jena
2023-12-27
Recruiting
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
NCT05280314Melanoma, Squamous Cell Carcinoma of Head and Neck
DrugsIO102-IO103·Pembrolizumab KEYTRUDA
IO Biotech
Phase 2
60
Essen, Heidelberg
2023-12-21
Active, closed
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475Cholangiocarcinoma
DrugTinengotinib
TransThera Sciences (Nanjing), Inc.
Phase 3
200
Baden, Frankfurt, Hamburg, Hanover, Heidelberg, München
2023-12-20
Recruiting
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157Neoplasms
DrugsMomelotinib·Ruxolitinib
Janssen Research & Development, LLC
Phase 1
300
Aachen, Berlin, Essen, Hanover, Heidelberg, Regensburg
2023-12-20
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,314
Freiburg im Breisgau, Heidelberg, Nürtingen, Munich, Regensburg, Marburg, Göttingen, Bergisch Gladbach
2023-12-18
Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
NCT06285318Relapsed/Refractory Multiple Myeloma (RRMM)
Janssen-Cilag Ltd.
Observational
900
Chemnitz, Dresden, Hamburg, Hanover, Heidelberg, Nuremberg, Würzburg
2023-12-18
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugNexiguran ziclumeran
Intellia Therapeutics
Phase 3
1,200
Berlin, Essen, Heidelberg, Würzburg
2023-12-13
Active, closed
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
NCT05734105GIST
DrugsRipretinib·Sunitinib
Deciphera Pharmaceuticals, LLC
Phase 3
54
Berlin, Essen, Heidelberg, Leipzig
2023-12-13
Recruiting
LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus
NCT05714930Systemic Lupus Erythematosus
Heinrich-Heine University, Duesseldorf
Not applicable
606
Freiburg im Breisgau, Heidelberg, Erlangen, Munich, Frankfurt am Main, Hanover, Düsseldorf, Essen
2023-12-12
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Bamberg, Cologne, Düsseldorf, Erlangen, Essen, Freiburg im Breisgau, Heidelberg, Homburg/Saar
2023-12-11
Recruiting
ThermoBreast - Non-contact Breast Cancer Imaging Using AI-enhanced Thermography.
NCT06266026Breast Cancer
ThermoMind Ltd.
Not applicable
28,000
Heidelberg
2023-12-11
Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945Multiple Myeloma
DrugsElranatamab·Pomalidomide·Dexamethasone
AstraZeneca
Phase 1/2
226
Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Lübeck, Nuremberg, Tübingen, Würzburg
2023-12-05
Recruiting
Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery
NCT06246136Open Angle Glaucoma
Elios Vision, Inc.
Not applicable
194
Bochum, Bonn, Heidelberg
2023-12-05
Recruiting
Multi-professional Care Pathway and Network for the Promotion of Needs-oriented, Resident-oriented Exercise Therapy for Oncological Patients
NCT06185777Cancer, Exercise, Implementation
University Hospital Heidelberg
Not applicable
2,500
Freiburg im Breisgau, Heidelberg, Tübingen, Frankfurt am Main, Mainz, Dresden, Berlin
2023-12-01
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
DrugsDatopotamab deruxtecan·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 3
625
Düsseldorf, Essen, Georgsmarienhütte, Hamburg, Hanover, Heidelberg, Heilbronn, Leipzig
2023-11-23
Recruiting
Feeding Tolerance and Growth of Preterm Infants Consuming a Supplement Containing Two Human Milk Oligosaccharides (HMOs)
NCT06212427Premature Infant, Low Birthweight Infant
Société des Produits Nestlé (SPN)
Not applicable
188
Berlin-Spandau, Darmstadt, Hamburg, Heidelberg, Nuremberg
2023-11-20
Recruiting
MR-guidance in Chemoradiotherapy for Cervical Cancer
NCT06142760Cervical Cancer
Juergen Debus
Not applicable
40
Heidelberg
2023-11-15
Recruiting
Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma
NCT05964569Low Grade Glioma
University Hospital Heidelberg
Phase 2
120
Heidelberg
2023-11-11
Recruiting
Plasma Extracellular Vesicles in Meningioma Patients
NCT06104930Meningioma
University Hospital Heidelberg
Not applicable
60
Heidelberg
2023-11-01
Active, closed
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332Metastatic Uveal Melanoma
DrugsDarovasertib·Crizotinib·Dacarbazine·Yervoy
IDEAYA Biosciences
Phase 2/3
420
Heidelberg, Cologne, Essen, Dresden, Berlin
2023-10-31
Recruiting
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
NCT06054035Type2diabetes, PreDiabetes, Renal Failure
DrugDapagliflozin
University Hospital Tuebingen
Phase 4
170
Berlin, Dresden, Düsseldorf, Heidelberg, Leipzig, Lübeck, München, Tübingen
2023-10-26
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
1,600
Esslingen am Neckar, Frankfurt, Gauting, Giesen, Heidelberg, Jena, Kempten, Lübeck
2023-10-26
Active, closed
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
NCT05598333Congestive Heart Failure
AskBio Inc
Phase 2
150
München, Berlin, Freiburg im Breisgau, Hanover, Heidelberg, Kiel
2023-10-20
Active, closed
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326Adenocarcinoma, Pancreatic Ductal
DrugsAutogene Cevumeran·MFOLFIRINOX·Tecentriq·Atezolizumab
Genentech, Inc.
Phase 2
260
Berlin, Bochum, Cologne, Dresden, Essen, Frankfurt, Hamburg, Heidelberg
2023-10-18
Active, closed
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806Multiple Myeloma
DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan
Celgene
Phase 3
79
Heidelberg, Ulm, Nuremberg, Cologne, Leipzig, Dresden, Essen, Hamburg
2023-10-16
Active, closed
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756Arteriosclerosis, Hypercholesterolaemia
DrugsEnlicitide Decanoate·Enlicitide
Merck Sharp & Dohme LLC
Phase 3
14,550
Bad Friedrichshall, Heidelberg, Mannheim, Nuremberg, Wallerfing, Bad Nauheim, Frankfurt am Main, Hanover
2023-10-09
Recruiting
JUMP_START - Optimization of Care for Young Cancer Patients with Gastrointestinal Tumors
NCT06621277Gastrointestinal Cancer
University Hospital Heidelberg
Observational
250
Heidelberg
2023-10-01
Active, closed
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT06088290Leiomyosarcoma
DrugsLurbinectedin·Doxorubicin
PharmaMar
Phase 3
469
München, Bad Saarow, Dresden, Hanover, Heidelberg, Manheim, Münster, Tübingen
2023-09-21
Active, closed
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
DrugAficamten
Cytokinetics
Phase 3
500
Berlin, Göttingen, Heidelberg, Jena
2023-08-31
Recruiting
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
NCT05958121Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
Immatics Biotechnologies GmbH
Phase 1/2
400
Heidelberg, Mannheim, Tübingen, Ulm, Erlangen, Nuremberg, Regensburg, Würzburg
2023-08-09
Active, closed
Comparing Decision on Aesthetics After Breast Cancer Locoregional Treatment.
NCT05196269Breast Cancer
Fundacao Champalimaud
Not applicable
1,030
Heidelberg
2023-08-08
Recruiting
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
NCT04808505Glycogen Storage Disease Type II Infantile Onset
DrugsCipaglucosidase alfa·Miglustat
Amicus Therapeutics
Phase 3
36
Giessen, Heidelberg, Höchheim, Münster
2023-07-18
Recruiting
Lung cAncer Robotic Comparative Study
NCT06038227Lung Cancer
Intuitive Surgical
Observational
600
Heidelberg, Regensburg
2023-07-15
Recruiting
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
NCT05332561Early-stage Breast Cancer
DrugsPhesgo·Ipatasertib·Inavolisib·Tecentriq
German Cancer Research Center
Phase 2
240
Heidelberg, Tübingen, Augsburg, Erlangen, Ulm, Würzburg, Dresden, Berlin
2023-06-29
Recruiting
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma
NCT05853965Multiple Myeloma, Multiple Myeloma in Relapse
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2
45
Hamburg, Chemnitz, Heidelberg, Lübeck, Ulm
2023-06-28
Active, closed
Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)
NCT05817942Ulcerative Colitis
DrugFilgotinib
Alfasigma S.p.A.
Observational
509
Grünwald, Amberg, Dachau, Hamburg, Heidelberg, Kiel, Leipzig, Münster
2023-06-12
Rows per page Showing 201–300 of 627
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/heidelberg?page=3

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 627 of those studies with a site in Heidelberg.

How many clinical trials are recruiting in Heidelberg?

333 of the 627 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 16 have not yet opened recruitment, 272 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.